BriaCell Therapeutics Corp.

TSX:BCT.TO

Biotechnology

Healthcare
$5.75 +18.88%

+$0.94 today

Market cap
$50.02M
Beta
1.53
P/E (TTM)
-0.3
EPS (TTM)
-$4.23
52W Low $3.68High $20.40

Volume 0.00M

Average 0.01M

BCT.TO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

BriaCell Therapeutics Corp.TSX: BCT.TO

Net Income · Q3 FY2026 · quarter ended Apr 2026

Net income grows, but more slowly than its trailing trend

Q3 FY2026 net income of $7.24M (cash outflow) rose 16.3% year over year, behind the +57.6% change in trailing-twelve-month net income. Sequentially, it fell 0.8% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.

Context

  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +16.3% toward the trailing-twelve-month pace of +57.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterApr 2026
-$7.24M-0.8% QoQ
Last fiscal yearJul 2025
-$26.63M+440.1% YoY
LTMApr 2026
-$30.88M+57.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.3%——
1 year+440.1%——
3-year CAGR-0.3%——
5-year CAGR——
10-year CAGR——

Net Income history

USD · from the cash flow

Latest · FY2025
(26.63M) USD
Year-over-year change
-440.1%

Net Income vs competitors

How BCT.TO compares with its peers on the latest reported figures

No competitor Net Income figures are available to compare.

Cash Flow Statement

USD
Metric
FY2021
Jul 2021
FY2022
Jul 2022
FY2023
Jul 2023
FY2024
Jul 2024
FY2025
Jul 2025
Net Income(13.82M)(26.84M)(20.3M)(4.93M)(26.63M)
Depreciation & Amortization15.26K15.27K15.27K83.9K107.93K
Deferred Income Tax00000
Stock-Based Compensation1.97M3.07M2.19M1.8M0
Change in Working Capital(2.28M)(391.29K)(3.53M)7.05M(1.93M)
Accounts Receivables9.94K(11.53K)5.23K(732.58K)742.6K
Inventory00000
Accounts Payables(1.41M)249.16K660.46K6.05M(3.93M)
Other Working Capital(886.38K)(628.93K)(4.2M)1.74M1.26M
Other Non-Cash Items6.36M11.66M(2.12M)(28.14M)(58.73K)
Operating Cash Flow(7.75M)(12.48M)(23.74M)(24.13M)(28.51M)
Capital Expenditures000(456.8K)0
Acquisitions (Net)000(225K)0
Purchases of Investments0000(7.74M)
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow000(681.8K)(7.74M)
Debt Repayment(330.4K)0000
Common Stock Issued51.62M04M4.42M46M
Common Stock Repurchased0(10.17M)(47.29K)00
Dividends Paid00000
Other Financing Activities13.71M6.43M1.59K00
Financing Cash Flow65M(3.74M)3.95M4.42M46M
Effect of Forex Changes0000(84.08K)
Net Change in Cash57.25M(16.23M)(19.79M)(20.39M)9.67M
Free Cash Flow(7.75M)(12.48M)(23.74M)(24.58M)(28.51M)

BriaCell Therapeutics Corp.

TSX:BCT.TO

Intrinsic Alpha fair value

Locked

Current Price

$5.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.